Company news

Faron Pharmaceuticals Oy (LSE:FARN) news

Faron Pharmaceuticals Oy news releases on 6ix. Latest, Jan 27, 2026: Faron Expands Bexmarilimab Program in Solid Tumors with a Randomized Phase I/II BEXAR IIT…

Faron Pharmaceuticals Oy (LSE:FARN) news

Press releases — page 2

Faron Expands Bexmarilimab Program in Solid Tumors with a Randomized Phase I/II BEXAR IIT in Metastatic Soft-Tissue Sarcoma

Faron Pharmaceuticals Ltd: PDMR Dealing

Faron Announces Strategic Collaboration with The Institute for Cancer Research to Launch BLAZE Trial, Targeting Immunotherapy Resistance in Cancer

Composition of Faron Pharmaceutical's Shareholders' Nomination Board

Composition of Faron Pharmaceutical’s Shareho...

Faron Issues Second Tranche of Bonds With an Aggregated Principal Amount of Eur 10 Million Under its Convertible Bond Arrangement

Faron issues second tranche of bonds with an ...

Faron Presents Updated BEXMAB Data at ASH 2025: Deep and Durable Responses in HR-MDS with Favorable Safety Profile

Faron Pharmaceuticals Ltd: Holding(s) in Company

Faron Pharmaceuticals Ltd: Holding(s) in Comp...

Faron Pharmaceuticals Ltd: Grant of Options

Faron Pharmaceuticals Ltd: Appointment of CFO

Faron's Financial Calendar for 2026

Faron’s Financial Calendar for 2026

Inside Information: Faron Intends to Issue Second Tranche of Bonds with an Aggregated Principal Amount of Eur 10 Million Under Its Convertible Bond Arrangement

INSIDE INFORMATION: FARON INTENDS TO ISSUE SE...

Faron Announces Two Bexmarilimab Abstracts Accepted At Ash 2025, Including An Oral Presentation On Treatment Efficacy

Faron Hits Key Milestone With Bexmab Phase 2 Completion, Advances To Registrational Trial With Fda Alignment

Updated BEXMAB Phase I/II Data Presented at ESMO 2025 Shows Further Improvement, Strengthening the Clinical Profile of Bexmarilimab in Treatment-Naïve HR-MDS Patients

Updated BEXMAB Phase I/II Data presented at E...

Faron Pharmaceuticals Ltd: Exercise of Options, Director Dealing and Issue of Equity

Faron Pharmaceuticals Ltd: Exercise of Option...

CORRECTION FROM SOURCE: Faron Pharmaceuticals Ltd: Half-Year Financial Results 1 January - 30 June 2025

Correction: FARON PHARMACEUTICALS LTD: HALF-Y...

Faron Pharmaceuticals Ltd: Half-Year Financial Results 1 January - 30 June 2025

FARON PHARMACEUTICALS LTD: HALF-YEAR FINANCIA...

Faron Pharmaceuticals Ltd: Notice of Half-Year Financial Results

Faron Pharmaceuticals Ltd: Notice of Half-Yea...

Inside Information: Faron to Advance Bexmarilimab into a Registrational Phase 2/3 Study in Treatment-Naïve (frontline) HR-MDS after Positive Meeting with the FDA

Inside Information: Faron to advance bexmaril...

Faron Announces Extension to its Key Patent Family around Bexmarilimab and Targeting Clever-1 in Cancers with a New US Patent Granted

Faron announces extension to its key patent f...

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds

Inside Information: Faron to Present Updated BEXMAB Data in Frontline HR-MDS to FDA; Complete Remission Rate Substantially Increased to 43%

Inside Information: Faron to present updated ...

Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at ESMO 2025

FARON ANNOUNCES ACCEPTANCE OF BEXMARILIMAB DA...

Faron Announces Acceptance of Two Studies Involving Bexmarilimab, One of Them as an Oral Presentation, at the 19th International Congress of Immunology (IUIS) 2025

Faron announces acceptance of two studies inv...

Faron Pharmaceuticals Ltd: Director Dealing

Faron Pharmaceuticals Ltd: Director/PCA Dealing

Faron Pharmaceuticals Ltd: Director/PCA Deali...

Faron-Supported Research in Theranostics Identifies Secreted Clever-1 (sClever-1) as an Independent Driver of Immune Evasion in Cancer, Deepening the Understanding of Bexmarilimab’s Mode of Action

Faron-supported research in Theranostics iden...

Faron Pharmaceuticals: Competitor study fails

Faron Pharmaceuticals: Further progress prese...

Faron Pharmaceuticals presents updated Phase II data from BEXMAB Study at EHA 2025

Faron Pharmaceuticals presents updated Phase ...

Faron Pharmaceuticals Ltd: Director/PCA Dealing and Donation of Shares to Foundation

Faron Pharmaceuticals: ASCO data supportive